Global Peptic Ulcer Drugs Market By Drug Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, H2-Antagonists, Antacids, Antibiotics, and Ulcer protective), By Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease, Gastritis, and Other Indications), By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 100148
- Number of Pages: 365
The Global Peptic Ulcer Drugs Market size is expected to be worth around USD 6.4 Billion by 2032 from USD 4.6 Billion in 2022, growing at a CAGR of 3.5% during the forecast period from 2023 to 2032.
The open sores developed in the stomach’s inside lining and the small intestine’s upper portion is called peptic ulcer. Generally, peptic ulcers are caused due to radiation therapy, inflammation, and frequent use of aspirins orally or parentally. If peptic ulcers are left untreated, they may lead to complications such as severe pain in the mid or upper-body parts, internal bleeding, weight loss, and severe blood loss, which needs hospitalization.
These complications are treated with peptic ulcer drugs, driving the demand for their availability and significantly increasing the market growth. The rising prevalence of peptic ulcers, especially in geriatric individuals, and the shifting of the consumer inclination towards different medications over invasive surgeries are the factors responsible for the growth of peptic ulcer drugs.
*Actual Numbers Might Vary In The Final Report
- Peptic Ulcer Overview: Peptic ulcers are painful sores that form on the mucosal linings of the stomach, small intestine, or esophagus and cause various symptoms including abdominal pain, heartburn and even bleeding in these organs.
- Etiology and Risk Factors for Peptic Ulcers: Peptic ulcers can be caused by factors like Helicobacter pylori infection, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), smoking cigarettes heavily consuming alcohol beverages or even stress.
- Drug Classes: Common medications prescribed to treat peptic ulcers include proton pump inhibitors (PPIs), H2-receptor antagonists, antacids, antibiotics (to eradicate H. pylori infection) and cytoprotective agents.
- Proton Pump Inhibitors (PPIs): PPIs are frequently prescribed to reduce stomach acid production, providing relief from symptoms while hastening ulcer healing.
- H2-Receptor Antagonists: H2-blockers work by decreasing stomach acid production. Their use helps alleviate symptoms while encouraging ulcer healing.
- Antacids: Antacids help neutralize stomach acid and can provide temporary relief of pain associated with peptic ulcers.
Antibiotics accounted for a dominant segment of the global peptic ulcer drugs market in 2022
Based on drug type, the market for peptic ulcer drugs is segmented into proton pump inhibitors, potassium-competitive acid blockers, H2-antagonists, antacids, antibiotics, and ulcer protection. Among these drug types, the antibiotics segment is the most dominant, mainly used in the peptic ulcer drugs market. It held the largest revenue share of 39% % in 2022.
The leading cause behind peptic ulcers is the bacteria known as H.pyroli. Antibiotics stand for first-line therapy, which includes one PPI and two antibiotics. Therefore, this results in higher adoption of antibiotics, making it a dominant segment. Second in the treatment option is proton pump inhibitors which are expected to grow at a significant CAGR over the forecast period.
By Indication Analysis
In 2022, the duodenal ulcer segment accounted for holding the largest revenue share of the global market for peptic ulcer drugs
Based on indication, the global market for peptic ulcer drugs is divided into a duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, gastritis, and other indications. The duodenal ulcer segment accounted for the largest market share in 2022 and is expected to continue its dominance during the forecast period. The rising prevalence of duodenal ulcers, increasing awareness, and therapeutic launches for its treatments are the factors predicted for this segment’s growth.
Moreover, the drugs for peptic ulcers are also effective in gastritis and gastroesophageal reflux disease, which is subjected to the further expansion of the market.
Distribution Channel Analysis
The hospital pharmacies dominated the peptic ulcer drugs market in 2022
The market is further classified by distribution channel into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to hold a dominant market share over the forecast period. The larger availability of peptic ulcer drugs at hospital pharmacies is positively driving the growth of this segment. The rise in the diagnosis of peptic ulcer patients and frequent hospital visits to get effective treatment is the key factor supporting its dominance.
Additionally, the popularity of online pharmacies is increasing among most people. Its convenience and ease will likely propel the growth of the online pharmacies segment over the forecast period.
Moreover, retail pharmacies offer generic drugs for peptic ulcers, which are affordable compared to branded drugs. Additionally, the OTC drugs for sudden stomach upsets and complications regarding gastric problems are further driving the market growth.
Key Market Segments
Based on Drug Type
- Proton Pump Inhibitors
- Potassium-Competitive Acid Blocker (P-CAB)
- Ulcer protective
Based on Indication
- Duodenal Ulcer
- Gastric Ulcer
- GERD (Gastroesophageal Reflux Disease)
- Other Indications
Based on Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Rising prevalence of peptic ulcer to support the market growth
The rising prevalence of peptic ulcers worldwide largely influences the market for peptic ulcer drugs. An ulcer develops when the stomach acid damages the stomach’s protective lining. This acid leads to the stomach’s open sores, resulting in bleeding and causing severe and intolerable pain. Peptic ulcer manifests itself in several ways, including gastric ulcers. Drugs that aids in the reduction of gastric secretion, such as PPIs, H2 receptor antagonists, antibiotics against H. pylori infection, and acid-neutralization agents, such as antacid, are used to treat peptic ulcers.
However, these medicines are administered frequently in combination to acquire a greater effect. Moreover, the rising usage of NSAIDS is one of the major reasons causing peptic ulcers and thus leads to the increase in demand for peptic ulcer drugs.
Awareness about the peptic ulcer drugs and sedentary lifestyle of individuals to propel the market growth
Rising initiatives by private and public organizations to spread awareness about peptic ulcer complications is likely to expand the growth of the peptic ulcer drugs market. Moreover, the sedentary lifestyle of individuals having an addiction to smoking and high alcohol consumption, which are the most common causes of peptic ulcer, increases the demand for peptic ulcer drugs and is expected to result in market expansion. An increase in disposable income and a rising geriatric population are the key factors predicted to contribute to the market’s growth over the forecast period.
The market growth is likely to expand due to the rising initiatives by private and public organizations to spread awareness about peptic ulcer complications. Moreover, individuals with a sedentary lifestyle have the habits such as addiction to smoking and high alcohol consumption, some of the most common causes resulting in peptic ulcer. These factors significantly increase the demand for peptic ulcer drugs and are anticipated to drive market growth positively.
Numerous ADRs associated with peptic ulcer drugs restrict the market growth
Despite the rising global prevalence of peptic ulcers, some factors are expected to limit the growth of the drug market. In Addition, ADRs associated with the usage of peptic ulcer drugs, such as the side effects of PPI, include the increased risk of gastroenteritis, nutritional deficiencies (vitamin B12, magnesium), bowel upset, and diarrhea.
The side effects associated with using anticholinergic drugs include dry mouth, urine retention, and constipation. Moreover, patent expiration and strict government regulations are responsible factors that are anticipated to restrict the growth of the global market for peptic ulcer drugs during the forecast period.
Increase in a strong pipeline of new drugs and increase in R&D activities to boost the market growth.
The increasing prevalence of peptic ulcers worldwide is propelling the major industry players to invest more in research & development activities. This involves launching a new drug for treating peptic ulcers, which will likely positively impact the peptic ulcer drug market.
Conducting clinical trials for investigational drugs to overcome the complications associated with the currently available drugs is another key factor expected to drive market growth during the forecast period.
Increasing adoption of OTC drugs to surge the market growth
A wide variety of OTC drugs are available for treating peptic ulcers in individuals. The approved OTC non-steroidal anti-inflammatory drugs allow faster and more affordable healthcare access, increasing their popularity and adoption among patients. Many peptic ulcer drugs, such as antacids, H2-receptor antagonists, antibiotics, and proton pump inhibitors, are available as OTC drugs. Many pharmaceutical companies are investing heavily in developing over-the-counter versions of peptic ulcer medications, which is anticipated to boost market expansion in the coming years.
North America held the maximum revenue share of the global market in 2022
Based on region, the global peptic ulcer drugs market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these regions, North America dominated the global peptic ulcer drugs market in 2022 with the largest revenue share of 43% and is expected to remain dominant over the forecast period. This is largely due to the surge in the use of (NSAIDs) such as aspirin and increasing awareness about the treatment options for peptic ulcers. These are major factors predicted to surge the growth of the peptic ulcer drugs market in North America.
Europe’s peptic ulcer drugs market holds the second-largest market share, owing to the easy availability of effective treatment options for peptic ulcers in this region.
The market for peptic ulcer drugs in Asia Pacific is anticipated to grow faster due to the development in healthcare infrastructure, the rising prevalence of peptic ulcers, and increasing awareness among the population. Latin America and, the Middle East & Africa are accounted to exhibit a lower growth rate due to the less awareness, unmet needs of healthcare, and a developing healthcare sector.
- The US
- The UK
- Rest of Western Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Key Players Analysis
Diverse & strong product portfolios, along with a well-organized distribution network worldwide, are the major factors attributable to the dominance of key players. These prominent players are actively involved in R&D activities resulting in strong regulatory approvals. Additionally, they are involved in strategic collaborations, partnerships, new product launches, mergers & acquisitions, significantly contributing to peptic ulcer drug market growth.
Below are some of the most prominent players in the global peptic ulcer drugs market
Market Key Players
- AstraZeneca plc
- Zydus Lifesciences Limited
- Boehringer Ingelheim International GmbH
- Novitium Pharma
- Yuhan Corporation
- Pfizer Inc.
- Pharmaking Co. Ltd.
- Viatris Inc.
- RedHill Biopharma Ltd.
- Novartis AG
- Other Key Players
Key Industry Developments
- In May 2020, the USFDA approved the three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule, RHB-105, from Michael E. De-Bakey Veterans Affairs Medical Center. This effectively eradicates Helicobacter pylori infection in adults.
- In July 2019, the USFDA approved Zydus Cadila’s Misoprostol tablets for treating stomach ulcers.
Report Features Description Market Value (2022) USD 4.6 Billion Forecast Revenue (2032) USD 6.4 Billion CAGR (2023-2032) 3.5% Base Year for Estimation 2022 Historic Period 2016-2021 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Drug Type – Proton Pump Inhibitors, Potassium-Competitive Acid Blockers, H2-Antagonists, Antacids, Antibiotics, and Ulcer protective; By Indication – Duodenal Ulcer, Gastric Ulcer, GERD(Gastroesophageal Reflux Disease), Gastritis, and Other Indications; By Distribution Channel Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; the Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Abbott, AstraZeneca plc, Zydus Lifesciences Limited, Boehringer Ingelheim International GmbH, Novitium Pharma, Yuhan Corporation
Pfizer Inc., Pharmaking Co. Ltd., Viatris Inc., RedHill Biopharma Ltd., Novartis AG, and Other Key Players
Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What is the global peptic ulcer Market?
The global peptic ulcer drugs market encompasses all products used to treat peptic ulcers - sores in the stomach lining or esophagus that affect eating or drinking habits - around the globe.What is the size of the global peptic ulcer drugs market?
The Global peptic ulcer drugs market size is expected to be worth around US$ 6.4 Bn by 2032 from US$ 4.6 Bn in 2022, growing at a CAGR of 3.5% during the forecast period from 2023 to 2032.What are the key factors driving the growth of the global peptic ulcer drugs market?
The Rising prevalence of peptic ulcer to support the market growth. Awareness about the peptic ulcer drugs and sedentary lifestyle of individuals to propel the market growth.Which regions have the largest share of the global peptic ulcer drugs market?
The regions having the largest share of the global peptic ulcer drugs market North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.Who are the major players in the global peptic ulcer drugs market?
The major players in the global peptic ulcer drugs market include Abbott, AstraZeneca plc, Zydus Lifesciences Limited, Boehringer Ingelheim International GmbH, Novitium Pharma, Yuhan Corporation, Pfizer Inc., Pharmaking Co. Ltd., Viatris Inc., RedHill Biopharma Ltd., Novartis AG, Other Key Players.What are some challenges facing the global peptic ulcer drugs market?
Some challenges facing the rising global prevalence of peptic ulcers, some factors are expected to limit the growth of the drug market. ADRs associated with the usage of peptic ulcer drugs, such as the side effects of PPI, include the increased risk of gastroenteritis, nutritional deficiencies (vitamin B12, magnesium), bowel upset, and diarrhea.What is the outlook for the global peptic ulcer drugs market?
The future looks bright for the global peptic ulcer drugs market, with increasing demand for combination therapies and development of new drugs anticipated to fuel its expansion in coming years. However, competitors such as generic medications may present challenges to this growth path and emergent threats could arise from such competition.
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|